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Abstract 
Background. Acquired thrombotic thrombocytopenic purpura is still associated with a 10-20% death 
rate. So far, early prognostic factors of death could not be clearly identified. To identify prognostic 
factors associated with 1-month death in thrombotic thrombocytopenic purpura patients with acquired 
severe (< 10% of normal activity) ADAMTS13 deficiency. 
 
Design and Methods. Prospective cohort of patients included between October, 2000, and August, 
2010. A validation cohort of patients was set up from September, 2010 to August, 2011. 281 (analysis 
cohort) and 66 (validation cohort) consecutive adult thrombotic thrombocytopenic purpura patients with 
acquired severe ADAMTS13 deficiency. 30-day mortality after treatment initiation according to 
characteristics at inclusion. 
 
Results. Non-survivors (11%) were older (P=10-6) and presented more frequently arterial 
hypertension (P=5.10-4) and ischemic heart disease (P=0.013). Prognosis was increasingly poor with 
age (p=0.004). On presentation, cerebral manifestations were more frequent in non-survivors (P=0.018) 
and serum creatinine level was higher (P=0.008). The most significant independent variables for 
determining death were age, severe cerebral involvement and LDH level ≥ 10N. A 3-level risk score for 
early death was defined and confirmed in the validation cohort using these variables, with higher values 
corresponding to increased risk of early death. 
 
Conclusions. A risk score for early death was defined in patients with thrombotic thrombocytopenic 
purpura and validated on an independent cohort. This score should help to stratify early treatment and 
intensify patients with a worse prognosis.
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Introduction 
Thrombotic thrombocytopenic purpura (TTP) is a severe form of thrombotic microangiopathy 
(TMA) characterized by profound thrombocytopenia, erythrocyte fragmentation and organ failure of 
variable severity. This rare disease results from an excessive systemic platelet aggregation caused by 
the accumulation of unfolded high molecular weight von Willebrand factor (VWF) multimers in 
plasma. This failure to degrade the endothelium-derived hyper-reactive VWF multimers into less 
adhesive forms is related to a severe deficiency in ADAMTS13 (A Disintegrin And Metalloproteinase 
with ThromboSpondin-1 like motifs), a protease specifically involved in this process (1). Severe 
ADAMTS13 deficiency results from biallelic mutations of the encoding gene in hereditary forms, or 
from polyclonal autoantibodies in acquired forms (2). These pathophysiological findings account for 
the efficiency of plasma-based treatment in TTP, which allows supplying ADAMTS13 deficiency. 
Immunomodulatory drugs aimed at depleting anti-ADAMTS13 antibody-producing B-lymphocytes are 
associated to standard treatment in an increasing number of cases (3, 4). Those therapeutical strategies 
allowed to improve outstandingly TTP prognosis, with overall survival rates which may reach 80-85% 
(5). Despite this significant progress, death still occurs in up to 20% of patients according to most large 
multicentre reports, usually within the first days of management. Interestingly, this incidence apparently 
did not improve for more than ~ 20 years according to some authors (6). Therefore, it is becoming 
essential to understand accurately the factors associated with a fatal outcome at the acute phase of the 
disease from large series of patients to better tailor initial treatment and further improve those results. 
So far however, the risk factors associated with death remain unclear. Severe clinical presentation on 
diagnosis, including cerebral involvement, renal failure (7), very low platelet count and profound 
anemia, was variably associated with a higher mortality rate by some authors (8, 9), but were not 
confirmed by others (7, 10-13). Patients at relapse were also reported as having a disease of better 
prognosis (14). Studies assessed the prognostic value of anti-ADAMTS13 antibodies, and inhibitory 
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anti-ADAMTS13 antibodies were associated with a more severe thrombocytopenia (15), a delayed 
response to standard treatment (16, 17) or an increased mortality rate (5, 6, 18). 
So far, the identification of accurate prognostic factors in TTP was hampered by the limited 
series of homogeneous patients. However, the increasing number of patients included prospectively in 
national registries should now help addressing this question. In this regard, we conducted a study from 
a large, homogeneous group of patients included in our registry. We report here original independent 
risk factors associated with 30-day death, and provide a prognostic score aimed at identifying at 
diagnosis patients at risk of fatal outcome who could possibly benefit from more intensive first-line 
therapies. 
 
Design and methods 
Study Design 
To assess prognostic factors associated with early death at the acute phase of TTP, we studied 
the characteristics of adult (≥ 18 year-old) patients who died during the 30-day period starting from 
treatment initiation (non-survivors group). These features were compared to those of patients who 
survived from their episode (survivors group). Patients of both groups were included during the same 
period of time from October, 2000 (date at which our registry was set up) (19) to the date of the study 
design (August, 2010). All patients were studied until death or durable remission. From this study 
group (learning group), we established a prognostic score to identify patients at risk of death during the 
episode of TTP using information at diagnosis. To validate our results on a prospective series of 
patients, a second group of patients (validation group) managed with the same conditions was set up 
from the same centers during the analysis period of the study group, i.e., from September, 2010 to 
August, 2011. All patients of the whole study were included nonselectively from intensive care units 
and departments of internal medicine, hematology, and nephrology in 39 French centers. The study 
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protocol was reviewed and approved by the institutional review board and ethical committee. An 
informed consent was obtained from all patients. 
 
Patients and Treatment 
All adult patients with a first episode of TTP associated with a severe acquired ADAMTS13 
deficiency (< 10% of normal activity) were enrolled in the study (6, 19 ; Supplemental appendix). To 
avoid the influence of inadequate plasma volumes in survival and to focus on the prognostic value of 
patient characteristics on diagnosis, we excluded patients who were not managed according to standard 
recommendations (Supplemental appendix and (4, 6)). 
 
Analysis 
Data were collected from diagnosis and before treatment (19), with a particular emphasis for a 
past history of cardiovascular risk factors (including arterial hypertension and diabetes) and a pre-
existing history of ischemic heart disease and ischemic stroke. Cerebral involvement assessment on 
diagnosis included headache, stupor, seizure and/or focal deficiency. Renal involvement was assessed 
by serum creatinine level and the estimated glomerular filtration rate (eGFR) by the Modification of the 
Diet in Renal Disease (MDRD) method. Measurement of ADAMTS13 activity, ADAMTS13 plasma 
inhibitor and anti-ADAMTS13 antibodies were performed as previously described (supplemental 
appendix and (20)).  
 
Statistical Analysis 
Quantitative variables were summarized by mean (standard deviation) and compared by the 
Wilcoxon rank-sum test; categorical data was summarized as count (%) and compared by the chi-
squared test or Fisher's exact test. Risk factors of early mortality were investigated by logistic 
regression. A univariable analysis was first carried out, and variables associated with mortality at the P 
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< .20 level were included in a backward multivariable analysis. Only variables associated at the .05 
level were kept in the final model. Multiple imputation was used for missing values. Using rounded 
coefficients from the linear predictor of the multivariable analysis, we designed a score for early death 
taking discrete values from 0 to 4. The score was validated by testing association of score with early 
death by TTP in a logistic regression. A cutoff value was obtained by maximizing the Youden score 
(sensitivity + specificity – 1), and the sensitivity, specificity, positive and negative predictive values and 
their respective 95% confidence intervals (95% CI) were determined. The area under the ROC 
(Receiver Operating Characteristic) curve was used to evaluate the discriminating power of our score. 
The difference in discriminating power between tests was tested using deLong procedure (21). 
Data were analyzed using the R software v2.9.  
 
Results 
1. Study group 
From October, 2000 to August, 2010, the Registry included 944 adult patients with a diagnosis 
of TMA and available data. Among them, 281 were considered as having a TTP with an acquired 
severe ADAMTS13 deficiency fulfilling all inclusion criteria of the study (Supplemental figure S1); all 
were followed during at least 30 days after treatment initiation. Thirty-three of those patients died 
during the 30-day period of observation, corresponding to 12% (95% CI [8%-15%]) death rate. The 
other patients were discharged alive.  
 
2. Univariable analysis for prognostic factors 
Table 1 details the clinical features of patients of the learning cohort on diagnosis according to 
outcome. Non-survivors were older (P = 10-6) and presented more frequently arterial hypertension (P= 
5.10-4) and ischemic heart disease (P = .013). On presentation, cerebral involvement including stupor 
and seizure were more frequently observed in non-survivors (P = .018, P = .014 and P = .004, 
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respectively). Serum creatinine level was higher (P = .008) and eGFR was lower (P  = 5.10-5) in non-
survivors. The incidence of inhibitory anti-ADAMTS13 antibodies and the titers for IgG anti-
ADAMTS13 antibodies were comparable between survivors and non-survivors. 
Age clearly showed the greatest impact on survival in our series. To get further insight on this 
feature, we analyzed the number of non-survivors according to age class (Table 2). We found that 
prognosis was increasingly poor with age, particularly in patients > 60 year-old (test for trend, P = 
.004). By comparing patients > 60 year-old with younger patients, we confirmed that elderly 
patients had a distinct presentation with more frequent cardiovascular risk factors and pre-existing 
comorbidities; organ injury was predominant (i.e., cerebral manifestations were more frequent and renal 
involvement was more severe), whereas anemia was less profound (supplemental Table 1). 
Most deaths (77%) occurred in the first 2 weeks following diagnosis (mean time from 
admission to death: 9.1±8.1 days). Deceased patients received a plasma volume of 346±303 
ml/kg. Death occurred in a context of one or multiple organ failure in relation with an uncontrolled 
TTP. Platelet count between diagnosis and death did not significantly increase (20±24x109/L versus 
25±40x109/L, respectively, P = .97). Non-survivors received steroids less frequently than survivors (P 
= .007). The use of salvage therapies (i.e., rituximab, vincristine, cyclophosphamide and 
splenectomy) was not different between survivors and non-survivors (P = NS for all). To assess 
whether rituximab could have influenced TTP prognosis in the more recent years, we compared the 
number of deceased patients before and after the rituximab era. We found that between those 2 periods 
(from 2001 to 2004 and from 2005 to 2010, respectively), the number of deceased patients was 
comparable (15/112 [13.4%] patients and 18/169 [10.7%] patients, respectively, P = .57), which 
apparently does not support a major role for rituximab in the improvement of TTP survival. Survivors 
achieved a durable complete remission within 23.7±23 days, and required a plasma volume of 
787±670 ml/kg. Platelets were infused in patients of both groups mainly for severe thrombocytopenia 
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soon after plasmatherapy was started, without apparent worsening of clinical condition. Dialysis was 
more frequently performed in non-survivors than in survivors (P = .001) (Table 3). 
 
3. Multivariable analysis  
Variables tested for inclusion in the model were age, arterial hypertension, cerebral 
involvement, LDH, serum creatinine and eGFR. Arterial hypertension was not retained in the model as 
it was strongly correlated with increasing age. Finally, increasing age, cerebral involvement and LDH 
level ≥ 10N were retained as risk factors in the multivariable model (Supplemental Table 2 and 
Table 4). On the basis of the coefficients of the multivariable regression, the following score was 
developed: cerebral involvement or LDH level ≥ 10N scored 1 point, an age between 41-60 years 
scored 1 point and an age above 60 years scored 2 points (Table 4). Table 5 reports mortality for 
patients by increasing score groups. The cutoff maximizing the Youden score was 3. Using this 
threshold, the sensitivity (% score ≥ 3 among non survivors) was 52% (95%CI, [35%, 67%]) and 
specificity (score < 3 among survivors) 90% (95%CI [86%, 93%]). The positive predictive value 
(mortality among those with a score ≥ 3) was 41% [95% CI, 28%, 57%] and negative predictive value 
(survival among patients with a score < 3) was 93% [95% CI, 89%, 96%]. The AUC was 0.77, 
showing that the score had discriminating ability (P < .0001) (Figure 1). 
 
4. Accuracy and validation of the prognostic score 
In the 66 patients included for validation (Clinical features on diagnosis are depicted in 
supplemental Table 3), 12 died in the 30 days after initial diagnosis. The scores calculated for this 
sample ranged from 0 to 3. There was increasing mortality with increasing score in the validation 
cohort (P < .025). The calibration of the model was also reasonable, as the observed number of 
deaths in each risk group compared with the expected number of deaths calculated using the 
predicted mortality from the model (Table 5). The mortality in the 9 patients with score ≥3 in the 
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validation sample was 33%, which was not different from the PPV calculated above (P = .36). Survival 
in the validation sample patients with score <3 was 84%, a little smaller than the 93% expected 
according to PNV (P = .01). 
 
Discussion 
We report herein a simple and reliable prognostic score for TTP regarding critical factors related 
to clinical presentation in a large group of homogeneous patients on diagnosis. The main finding of our 
work is the emphasis that age-related categorization is important for evaluation of survival. Indeed, we 
provide here strong evidence that TTP in the elderly has a more aggressive presentation, with a more 
severe organs dysfunction (as illustrated here by a higher incidence of cerebral involvement and a more 
severe renal involvement, with more stupor and seizure and a higher serum creatinine level, 
respectively) and, consequently, a higher death rate. Previous retrospective studies with a more limited 
number of patients also emphasized that non-survivors were older than survivors (13, 22-24). A more 
severe neurologic and/or renal involvement was also reported in non-survivors, in accordance with our 
findings (7, 8, 13, 22, 24, 25). By contrast, we were unable to correlate the severity of cytopenias and 
the presence of fever with prognosis (13, 25). Despite those inconsistencies, which may be due to 
differences in inclusion criteria and in the size of the cohorts, an increasing number of studies including 
ours support clear evidence that age strongly impacts TTP prognosis. 
The more severe prognosis of TTP in older patients can be explained by different ways. First, 
most patients in our study had a history of arterial hypertension, which results in chronic endothelial 
and vascular dysfunction that worsens with ageing (26). In line with those features, patients in non-
survivors group, which included a large number of old patients, had more frequently a history of 
ischemic heart disease. Second, ageing is physiologically associated with vascular senescence and loss 
of vascular compliance (27) that may result in a higher shear stress and to more severe vascular wall 
constraints and more organ injury during TTP. Moreover, the very high LDH level we identified as a 
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factor of worse prognosis reflects a severe multiple organ involvement (28) which may include not only 
brain and kidney, but also heart, digestive tract, adrenal glands, pancreas and liver (29). In particular, 
cardiac involvement was associated with a high incidence of morbidity and mortality (30-32), and it is 
likely that the evaluation of this latter should improve the accuracy of our prognostic score. 
 Despite standard treatment, the mortality of TTP in high risk categories may range from 30% to 60%. 
Therefore, our score should be of help in the early management of these patients to discuss whether or 
not additional therapies should be added to standard treatment soon after diagnosis. Among these, 
rituximab could be a promising strategical therapy in this context, though its efficiency is not 
immediate (4). Some reports suggested that the administration of very high volumes of plasma could 
improve the prognosis of the more severe patients (33). As a perspective point of view, old patients 
with a diagnosis of TTP should benefit from more intensive supportive care and should be monitored 
more closely in intensive care units with more aggressive attention to cardiac and renal function. Also, 
forthcoming studies should evaluate the role of promising adjunctive therapies in those patients (34), 
and our score should help to identify accurately the more suitable patients for such studies.  
One limitation of our study is some variation in the treatment of patients throughout the 
inclusion period; particularly, there were an increasing number of patients with a suboptimal response 
to standard treatment treated with rituximab, which may have influenced TTP prognosis in the more 
recent years. However, the number of deceased patients was comparable throughout the inclusion 
period, and particularly before and after the rituximab era. Similarly, steroids were administered more 
frequently in survivors, though this difference was not significant by multivariable analysis. Therefore, 
whether steroids impacted prognosis in our study remains unknown and it is likely that steroids were 
less frequently administrated in non-survivors because this group included a large number of old 
patients for whom steroids are usually prescribed with reluctance. 
In conclusion, we provide here a reliable score predictive of death in TTP with acquired severe 
ADAMTS13 deficiency, which should help to tailor treatment on admission. We provide strong 
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evidence that age is an important prognostic factor. In patients with a severe score, more intensive 
therapies should be considered and evaluated on prospective trials.
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Table 1. Clinical characteristics of patients on diagnosis according to outcome. 
 Survivors 
(N=248) 
Non-survivors 
(N=33) 
P-value 
Ethnicity 
    Caucasians 
    Afro-Caribbeans 
    Others 
 
209 (86) 
26 (11) 
9 (4) 
 
29 (85) 
3 (9) 
0 
 
0.70 
Age (year-old) 39.2 ± 15.7      56.5 ± 19.4      10-6   
Females 167 (67) 23 (70) 0.79 
Cardiovascular risk factors and 
pre-existing comorbidities 
    Arterial hypertension 
    Diabetes 
    Ischemic stroke 
    Ischemic heart disease 
 
 
25 (10) 
16 (6) 
6 (2) 
11 (4) 
 
 
11 (33) 
3 (9) 
0 (0) 
5 (15) 
 
 
5.10-4 
0.57 
0.37 
0.013 
Cerebral involvement 
    Headache 
    Stupor 
    Seizure 
    Focal deficiency 
145 (59) 
62 (25) 
34 (14) 
16 (6) 
41 (17) 
27 (82) 
5 (15) 
10 (30) 
7 (21) 
10 (30) 
0.018 
0.21 
0.014 
0.004 
0.94 
Fever 60 (25) 9 (28) 0.69 
Hemoglobin level (g/dL) 7.9 ± 2.0        7.9 ± 2.5        0.73    
Reticulocyte count (N=179) 202 ± 126 157 ± 91 0.15    
LDH level (xN) (N=232)$ 5.8 ± 4.2        8.3 ± 4.8        0.06 
LDH ≥ 10N (%) (N=232) 22 (9) 6 (21) 0.05 
Platelet count (x109/L) $ 19.1 ± 19.0      20.0 ± 23      0.97    
Serum creatinine (µmol/L) $ 116 ± 88   172 ± 118   0.008    
Estimated glomerular filtration 
rate (mL/min) $ 
72.1 ± 31 50.8 ± 33 5.10-5 
ANA (N=253) 114 (50) 13 (52) 0.84 
APLA (N=187) 18 (11) 2 (10) 0.86 
ADAMTS13 inhibitor 
(N=177) 
118 (74) 13 (72) 0.92 
IgG anti-ADAMTS13 Abs 
(U/mL) (N=90)  
97 ± 106 183 ± 366 0.28 
Abbreviations: xN: number of times the upper normal value; ANA: antinuclear antibodies; APLA: 
antiphospholipid antibodies; Abs: antibodies. $: Test on the Log scale. In case of missing values, the 
number of patient tested is specified in parentheses in the left column. 
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Table 2. Mortality rate in patients according to age class. 
 
Age (years) (N) Deceased patients % [CI 95%]* 
< 30 (92) 
30-40 (51) 
40-50 (53) 
50-60 (42) 
60-70 (22) 
> 70 (21) 
4 
2 
6 
7 
5 
9 
4 % [2% - 11%] 
4% [1% - 13%] 
11% [5% - 23%] 
17% [ 8% - 31%] 
23% [10% - 43%] 
43% [24% - 63%] 
Abbreviation: N: number of patients; CI: confidence interval. 
* Test for trend, P = .004. 
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Table 3. Characteristics of patients’ management according to outcome. 
 Survivors 
(N=248) 
Non-survivors 
(N=33) 
p-value 
Steroids (N=32) 199 (80) 19 (59) 0.007 
Rituximab 75 (30) 5 (15) 0.07 
Splenectomy 12 (5) 1 (3) 0.64 
Vincristine 43 (17) 6 (18) 0.90 
Cyclophosphamide 10 (4) 0 (0) 0.24 
Platelets infusion (N=267) 100 (43) 15 (47) 0.64 
Hemodialysis (N=263) 6 (2.4) 4 (27)$ 0.001 
Data are given as number of cases (%). In case of missing values, the number of patient tested is 
specified in parentheses in the left column. 
$
 The analysis was performed from 15 patients.
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Table 4. Association between patients’ characteristics and outcome by multivariable analysis. 
 Odds Ratio 95% CI p-value Score 
Cerebral involvement 2.6 [1.0, 6.9] 0.05 +1 
Age  
 ≤40 
 41-60 
 > 60  
 
 
1 
3.4 
10.6 
 
- 
[1.2, 9.7] 
[2.0, 32.0] 
 8.10-6  
+0 
+1 
+2 
 
LDH level ≥ 10N 3.0 [1.3, 11.6] 0.014 +1 
Abbreviations: CI, confidence interval; N: number of times the upper normal value. 
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Table 5. Prognostic score of thrombotic thrombocytopenic purpura mortality in the learning cohort and 
in the validation cohort.  
Risk group Score Learning cohort 
  N          % death [95% CI] 
Validation cohort  
   N     % death [95% CI]    Observed/Expected* 
 
Low 
0 62 3 [0.9, 11.0] 12 0 [0, 25] 0 / 0.2 
1 99 5 [2.1, 11.3] 23 13 [5, 32] 3 / 1.1 
Intermediate 2 79 11 [6.1, 20.3] 22 27 [13, 48] 6 / 3.3 
 
High 
3 38 39 [25.6, 55.3] 9 33 [12, 65] 3 / 3.2 
4 3 66 [20.8, 98.3] - - - 
Abbreviations: N: number of patients; CI: confidence interval. 
* Expected deaths are based on model predicted mortality. 
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Figure 1. ROC (Receiver Operating Characteristic) curve. The AUC (area under the curve) was 0.77, 
showing that the score had discriminating ability (P<0.0001). The present score (full line) had better 
discriminating ability than the Wyllie score (broken line) (deLong test, P<0.0035).13 
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Supplemental Table 1. Clinical characteristics of patients on diagnosis according to age. 
 Age ≤ 60 
(N=241) 
Age > 60 
(N=40) 
P-value 
Ethnicity (%) 
    Caucasians 
    Afro Carribeans 
    Others 
 
86 
11 
3 
 
90 
5 
5 
0.386 
Females (%) 68 65 0.718 
Cardiovascular risk factors and 
pre-existing comorbidities (%) 
    Arterial hypertension 
    Diabetes 
    Ischemic stroke 
    Ischemic heart disease 
 
 
6 
4 
1 
4 
 
 
52.5 
33 
7.5 
17.5 
 
 
9.10-12 
4.10-5 
6.10-5 
4.10-5 
Cerebral involvement 
    Headache 
    Stupor 
    Seizure 
    Focal deficiency 
 
27 
13 
6 
27 
 
5 
32.5 
20 
60 
 
0.001 
0.004 
0.008 
0.185 
Fever 23 37.5 0.075 
Hemoglobin level (g/dL) 7.8 ± 2 8.4 ± 2.5 0.073 
Reticulocyte count (N=179) 204 ± 127 154 ± 89 0.067 
LDH level (xN) 6.0 ± 4.2 5.5 ± 3.6 0.597 
LDH > 10N (%) 13 5 0.274 
Platelet count (x109/L)  18 ± 17 25 ± 30 0.355 
Serum creatinine (µmol/L) 116 ± 90 164 ± 104 0.002 
Estimated glomerular filtration 
rate (mL/min)  
73 ± 32 47 ± 25 2.10-6 
ANA (N=253) 52 37.5 0.135 
APLA (N=187) 9 21 0.147 
ADAMTS13 inhibitor 
(N=177) 
113 (74) 18 (72) 0.809 
IgG anti-ADAMTS13 Abs 
(N=126) (U/mL) 
109 ± 169 97 ± 70 0.751 
Death (%) 8.3 32.5 0.0001 
DOI: 10.3324/haematol.2011.049676
Abbreviations: xN: number of times the upper normal value; ANA: antinuclear antibodies; 
APLA: antiphospholipid antibodies; Abs: antibodies. In case of missing values, the number of 
patient tested is specified in parentheses in the left column. 
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Supplemental Table 2. Full model of logistic regression. 
  Odds Ratio 95% CI p-value 
Cerebral involvement 2.7 [1.0, 7.7] 0.042 
Age  
 ≤40 
 41-59 
 ≥ 60  
  
1 
2.2 
3.5 
  
- 
[0.7, 6.7] 
[1.3, 18.4] 
0.024 
Serum creatinine (µmol/L) 0.998 [0.95, 1.05] 0.93 
Estimated glomerular filtration 
rate (mL/min) 
0.84 [0.68, 1.04] 0.10 
LDH level ≥ 10N 3.1 [1.0, 9.6] 0.047 
Abbreviations: 95% CI: 95% confidence interval; xN: number of times the upper normal value. 
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Supplemental Table 3. Clinical characteristics of patients on diagnosis according to outcome 
in the validation cohort. 
 Survivors 
(N=54) 
Non-survivors 
(N=12) 
P-value 
Ethnicity (N=47) 
    Caucasians 
    Afro-Caribbeans 
    Others 
 
30 (65) 
10 (21) 
7 (19) 
 
12 (100) 
0 (0) 
0 
 
0.07 
Age (year-old) 38.7 ± 13.1 49.6 ± 14.7      0.027 
Females 46(85) 8 (67) 0.21 
Cardiovascular risk factors and 
pre-existing comorbidities 
(N=63) 
    Arterial hypertension 
    Diabetes 
    Ischemic stroke 
    Ischemic heart disease 
 
 
 
8 (15) 
2 (4) 
2 (4) 
1 (2) 
 
 
 
1 (10) 
0 (0) 
1 (10) 
0 (0) 
 
 
 
1 
1 
0.43 
1 
Cerebral involvement 
    Headache (N=64) 
    Stupor 
    Seizure 
    Focal deficiency 
37 (68) 
31 (60) 
7 (13.5) 
4 (8) 
17 (33) 
10 (83) 
2 (20) 
5 (42) 
1 (8) 
7 (58) 
0.48 
0.01 
0.039 
1 
0.013 
Fever (N=54) 5 (11) 3 (30) 0.15 
Hemoglobin level (g/dL) (N=58) 8 ± 2.0        8.3 ± 1.5        0.54 
Reticulocyte count (N=33) 213 ± 158 228 ± 110 0.33 
LDH level (xN) 4.8 ± 2.8        8.1 ± 4.6        0.008 
LDH > 10N (%) 4 (7.4) 3 (25) 0.11 
Platelet count (x109/L) (N=61) 21 ± 18      14 ± 10     0.12 
Serum creatinine (µmol/L) 
(N=51) 
117 ± 102   130 ± 68  0.43 
Estimated glomerular filtration 
rate (mL/min) (N=51) 
71.3 ± 29 56.7 ± 27 0.27 
ANA (N=43) 19 (53) 5 (71) 0.44 
APLA (N=18) 1 (7) 0 (0) 1 
ADAMTS13 inhibitor 
(N=59) 
43 (88) 8 (80) 0.61 
IgG anti-ADAMTS13 Abs 
(U/mL) (N=46)  
77 ± 54 111 ± 73 0.16 
DOI: 10.3324/haematol.2011.049676
xN: number of times the upper normal value; ANA: antinuclear antibodies; APLA: 
antiphospholipid antibodies; Abs: antibodies. In case of missing values, the number of patient 
tested is specified in parentheses in the left column. 
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Supplemental figure 1. Flow diagram of the study.  
From the 944 patients of our registry, 610 were not included in the present study because of 
an associated condition (327 cases) or a detectable ADAMTS13 activity (283 cases). From 
the remaining patients with an undetectable ADAMTS13 activity and considered as having a 
TTP, 38 had a past history of TTP and 12 were not treated according to our standard 
guidelines (in most cases, TPE were not performed daily), leaving 281 patients for analysis. 
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